B3GAT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, Hughes et al. [25] reported that CML patients who achieved a DMR after TKI therapy had a more mature cytolytic CD57+ NK cell phenotype, with a normal restoration of this compartment, increased effector cytotoxic T lymphocytes capable of inducing an immune response against leukemia associated antigens and reduced immune myeloid derived suppressor cells and Tregs.